<DOC>
	<DOCNO>NCT01296360</DOCNO>
	<brief_summary>This randomize , open-label Phase 3 study include child age &gt; 9 month &lt; 17 year 7 month vaccinate IXIARO study IC51-323 .</brief_summary>
	<brief_title>Open-label , Randomized Study Pediatric Population JEV ( Japanese Encephalitis Virus ) -Endemic Country</brief_title>
	<detailed_description>This randomize , open-label Phase 3 study include child age &gt; 9 month &lt; 17 year 7 month vaccinate IXIARO previous study IC51-323 .</detailed_description>
	<mesh_term>Encephalitis</mesh_term>
	<mesh_term>Encephalitis , Japanese</mesh_term>
	<criteria>Children adolescent complete study IC51323 receive IXIARO vaccination accord protocol . Children receive dose confirm age group . Male female healthy child adolescent age â‰¥9 month &lt; 17 year 7 month time enrolment study . Written inform consent subject 's legal representative ( ) , accord local requirement , write informed assent subject , applicable . Female subject : either childbearing potential negative pregnancy test ( pregnancy test perform female subject onset menarche ) Visits 1 , 2 2a stipulate protocol . For female menarche willingness practice reliable method contraception Vaccination JE virus ( JEV ) ( except within study IC51323 IC51 325 ) , Yellow fever , West Nile virus Dengue fever time prior plan study . History clinical manifestation Flavivirus disease IC51323 IC51 325 . Participation another study investigational drug IC51 323 IC51 325 . Planned active passive immunization within 2 week 1 week IXIARO booster . History development immunodeficiency include postorgantransplantation inclusion IC51323 IC51 325 . History development autoimmune disease study IC51323 IC51 325 . Administration chronic ( defined 14 day ) immunosuppressant immunemodifying medication start IC51323 IC51 325 . ( For corticosteroid , would mean prednisone equivalent &gt; 0.05 mg/kg/day ; topical inhale steroid allow ) . Acute febrile infection Visit 2 ( Booster Group ) . Pregnancy ( positive pregnancy test Visit 1 Visit 2 ) , lactation unreliable contraception female subject onset menarche . Hypersensitivity reaction IXIARO adverse event study IC51323 require withdrawal vaccination anaphylaxis severe case atopy require emergency treatment hospital admission IC51323 IC51 325 . History urticaria hymenoptera envenomation , drug , physical provocation idiopathic cause IC51323 IC51 325 . Known infection human immunodeficiency virus ( HIV ) , hepatitis B virus ( HBV ) ( measurement Hepatitis B surface antigen [ HBsAg ] titer ) hepatitis C virus ( HCV ) . Illicit drug use and/or current drug alcohol addiction . Inability unwillingness legal representative ( ) and/or subject ( applicable ) provide inform consent/assent abide requirement study . Persons committed institution ( court authority ) .</criteria>
	<gender>All</gender>
	<minimum_age>9 Months</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>immune response</keyword>
	<keyword>IC51-325</keyword>
	<keyword>Japanese Encephalitis</keyword>
	<keyword>Intercell AG</keyword>
</DOC>